Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial med. app.

By: Toms SA, Kim CY, Nicholas G, Ram Z
Published in: J Neurooncol 2019; 141 (2): 467-473
Download citation in RIS format

Exposure